Fresh frozen plasma (FFP) 
Fresh frozen plasma (FFP) is widely used in clinical practice, 1 despite indications for the use of this blood component being limited to a few conditions, [2] [3] [4] such as the treatment of bleeding associated with an abnormal coagulation test result, patients having a bleeding tendency combined with disseminated intravascular coagulation, clotting-factor deficiencies-congenital or acquired-and some rare bleeding disorders. A variety of adverse effects of transfusion, including nonhemolytic febrile reaction, allergic reaction due to plasma-protein incompatibility, transfusion-transmitted viral diseases, and transfusion-related acute lung injury, may occur during or after FFP transfusion. [5] [6] [7] [8] [9] Despite an increased awareness of the risks involved, the prescription of inappropriate transfusions remains a significant problem. 8, 9 Owing to the lack of consensus regarding the appropriateness of FFP transfusion, blood banks find it difficult to control the use of FFP clinically. Few studies concerning the appropriate use of FFP in clinical practice have been reported.
Computer-based clinical decision support systems have been shown to improve physician performance and inpatient outcomes. 10, 11 We previously reported the appropriateness and physician compliance of platelet use when using a computerized transfusion decision support system (CTDSS), established in September 2004 at Kaohsiung Medical University Hospital (KMUH; Kaohsiung, Taiwan)-an academic medical center with 1,400 beds. 12 In addition, we reported that periodic auditing might change the amount of FFP used and improve the quality of transfusion after the intervention of the computerized system. 13 However, questions regarding the physician compliance with the transfusion guidelines in the CTDSS and the appropriateness of the FFP use remain uncertain. In this study, we investigated physician compliance and the appropriateness of FFP use by using the CTDSS, thus building up the evidence base regarding current FFP transfusion practice in a medical center.
Materials and Methods

Collection of Data for the Study
We retrospectively reviewed all FFP transfusion data between January and December 2008. The demographic data, including sex, blood type, disease type, patient source, functional unit, and the transfusion indication chosen from the CTDSS, were obtained from the computerized hospital information system (CHIS) of KMUH. The patients' latest coagulation tests, including prothrombin time (PT), international normalized ratio (INR) of PT, and activated partial thromboplastin time (aPTT) before and after transfusions, were retrieved from the laboratory information system database.
Criteria for FFP Use in KMUH
The FFP use criteria established by the KMUH transfusion committee and used as a computerized transfusion guide are as follows: (1) abnormal coagulation test results with INR or aPTT ratio more than 1.5, and bleeding, preoperative status, or undergoing an invasive procedure; (2) need for massive transfusion with blood volume exceeding 1 total blood volume; (3) need for plasma exchange; (4) bleeding tendency due to deficiency of antithrombin III or protein C or S or undergoing anticoagulation treatment; (5) bleeding tendency due to disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome; (6) emergency heart surgery or other operations without aPTT or PT tests; and (7) other conditions approved by a physician in the blood bank. One of the preceding criteria would be chosen by the physician from the CTDSS before completing an FFP transfusion order.
Appropriateness of FFP Use
An appropriate transfusion order is defined as a blood product ordered with an indication that satisfies the criteria. 8 After excluding the episodes for plasma exchange, for massive transfusion with blood volume exceeding 1 total blood volume, and for patients undergoing emergency heart surgery or other operations without aPTT or PT tests, each FFP request was classified in our study as "indicated," "unknown indication," or "not indicated." An indicated FFP use in our study was determined mainly according to the abnormal coagulation test results before transfusion. An order without sufficient information or coagulation results before ordering was classified as having an unknown indication. A request with sufficient information but that did not meet our FFP transfusion criteria was classified as not indicated. The flow diagram used to determine the appropriateness of FFP transfusion practice is shown in ❚Figure 1❚.
Evaluation of the Therapeutic Efficacy of FFP Transfusion
The pretreatment and posttreatment laboratory results, including INR and aPTT ratio from CHIS, were used to evaluate the therapeutic efficacy of FFP transfusion. Treatment with plasma was determined as effective when it corrected or improved previously abnormal coagulation test results. This analysis was carried out for patients for whom pretransfusion and posttransfusion coagulation data were available. Two subgroups were formed: patients with "normal" and "abnormal" pretransfusion coagulation results according to the threshold prolongation of PT and aPTT more than 1.5 times the normal range. The 2 subgroups did not include patients with a diagnosis of thrombotic thrombocytopenic purpura. These factors were analyzed by t tests for paired data, and P values less than .05 were considered statistically significant.
Results
Characteristics of the Episodes
A total of 10,926 episodes of FFP transfusion were ordered from January to December 2008 for patients enrolled in the study. ❚Table 1❚ shows the distribution of the 
Percentage of Indications From the CTDSS
The percentages of indications for FFP use according to the CTDSS are shown in ❚Table 2❚. The 9,642 episodes chosen (88.2%) had at least 1 indication from the CTDSS when ordering. The most common indication for FFP use was "abnormal coagulation test results with INR or aPTT ratio more than 1.5 and bleeding, preoperative status, or undergoing an invasive procedure" (7,096 [73.6%]). Other indications chosen were no more than 10% of the total. Finally, 1,284 episodes (11.8%) did not show any indication from the CTDSS when ordering.
The Appropriateness of FFP Use
The flow diagram representing the FFP transfusion practice to determine "appropriateness" is shown in Figure  1 . In total, 9,931 episodes were evaluated, after excluding the episodes for plasma exchange, massive transfusion with blood volume exceeding 1 total blood volume, and emergency heart surgery or other operations without aPTT or PT tests. Among these evaluated episodes, 3,232 (31.5%) were classified as indicated, 1,307 (13.2%) unknown indication, and 5,492 (55.3%) not indicated.
Evaluation of the Therapeutic Efficacy of FFP Transfusion
To study the therapeutic efficacy of FFP transfusion, cases with pretreatment and posttreatment coagulation results (INR or aPTT ratio) were retrieved from the CHIS for evaluation. The pretransfusion and posttransfusion data were measured in 1.22 ± 1.42 days (range, 1-5 days) and 2.13 ± 1.22 days (range, 1-5 days), respectively. The results are shown in ❚Table 3❚. There were 1,735 episodes with a pretransfusion INR value greater than 1.5 (mean ± SD, 2.06 ± 1.13), including 478 cases with an aPTT ratio less than 1.5, 855 with an aPTT ratio greater than 1.5, and 402 without aPTT data. The mean ± SD posttransfusion INR of these cases was 1.79 ± 0.73, which was significantly lower than the pretransfusion INR (P < .001). Similar results were also observed in the 604 episodes having a pretransfusion aPTT ratio greater than 1.5 (Table 3) . It is interesting that for cases with a PT INR or aPTT less than 1.5, our results showed a mildly increased posttransfusion PT INR or aPTT ratio, respectively (Table 3) .
Discussion
Among the 10,926 FFP transfusion episodes, 1,284 (11.8%) were performed without choosing any indication from the CTDSS when ordering (Table 2) , and 3,786 (34.7%) episodes used the indication of abnormal coagulation test results with an INR or aPTT ratio of more than 1.5 and bleeding, preoperative status, or undergoing an invasive procedure, although the patients showed normal coagulation results (results not shown). We define these episodes as poor physician compliance in our study, the noncompliance rate being 46.5%. However, a noncompliant transfusion order does not always mean inappropriate use. A noncompliant but appropriate episode may occur when the clinical status satisfies the FFP use criteria but the physician does not pick any indication from the CTDSS when ordering, probably because of the urgent or unstable nature of the emergency department entrants or surgical patients. The rate of appropriate use under noncompliance is 28.1% in our study.
After excluding the episodes for plasma exchange, massive transfusion with blood volume exceeding 1 total blood volume, and emergency heart surgery or other operations without aPTT or PT tests, there were 5,492 (55.3%) evaluated FFP transfusion episodes classified as not indicated. Most of them showed normal laboratory coagulation results and did not show any evidence of need for FFP. Some of the episodes chosen as no indication or other conditions approved by a physician in the blood bank are also classified as not indicated because the FFP use seemed unnecessary after evaluating the clinical status documented in the CHIS. Moreover, 1,307 episodes (13.2%) were classified as unknown indication because they did not have sufficient information or coagulation results to make a decision regarding FFP transfusion. If these 2 subgroups (not indicated and unknown indication) are defined as inappropriate FFP use, the percentage of inappropriate use in our study is 68.5%. This finding is similar to the results published in other studies. [14] [15] [16] However, as discussed previously, assessment of the appropriateness of FFP use by reviewing the CHIS could be limited by incomplete documentation, which may have resulted in missing important clinical information to judge the appropriateness of FFP use. 12 In addition, our evaluation of the appropriateness of FFP use excluded the episodes for plasma exchange, massive transfusion with blood volume exceeding 1 total blood volume, and emergency heart surgery or other operations without aPTT or PT tests, which may have resulted in a lower proportion of inappropriate orders. In addition, another limitation in our study is that the definition of inappropriateness did not take into account the dose of FFP given.
About 50% of the FFP transfusion episodes were in the hepatobiliary division (40.7% internal medicine and 8.3% surgery). This might be due to the high incidence of liver cirrhosis and hepatoma in Taiwan that is related to the epidemics of hepatitis B and C. [17] [18] [19] [20] [21] However, there is little evidence of the efficacy of FFP in liver cirrhosis, [22] [23] [24] hypoproteinemia, or nutritional applications 25 ; hence, no consensus exists for its use in these cases. Nevertheless, the patients received most of the FFP requests in KMUH. Consensus on the use of FFP in such cases to facilitate appropriate use is needed in addition to further prospective research in this area. By using the threshold prolongation of PT and aPTT more than 1.5 times the normal range in the retrospective studies and the criteria set by the College of American Pathologists in 1994, 26, 27 we evaluated the efficacy of FFP transfusion in our cases. In real-world clinical practice, it is difficult to get the results of coagulation tests just before and after FFP transfusion and to evaluate the subsequent efficacy of treatment. Iorio et al 16 noted a significant improvement in INR after FFP transfusion. Our results showed that patients with abnormal pretransfusion coagulation data had significant improvement in the INR and aPTT ratio after FFP transfusion (P < .001). However, in patients with normal pretransfusion coagulation results, FFP transfusion showed no further shortening of the PT or aPTT. On the contrary, there was a significant threshold prolongation of PT or aPTT in this subgroup. Although the main purpose of FFP transfusion is to provide coagulation factors to patients with coagulation factor deficiency, there is insufficient evidence to conclude that abnormal coagulation results can predict bleeding. Multiple observational studies point to a lack of predictive effects for bleeding risk in patients with mild or moderate abnormalities determined in coagulation tests 28 and, thus, indicate that coagulation results are only crude predictors of surgical bleeding. 29, 30 Our results provide a further basis to try to understand the manner in which physicians request blood transfusions and, thus, collect further evidence of the efficacy of FFP use.
Salem-Schatz et al 31 showed the computerized decision system as an effective tool to improve physician performance, compliance with criteria, and patient outcome. Although there is a well-established CTDSS in KMUH to help physicians order FFP appropriately and improve transfusion quality, it has no power to reject inappropriate transfusion requisitions. Transfusion episodes without any indication or sufficient evidence such as abnormal coagulation data when ordering FFP use are still accepted. Thus, 3,786 FFP units (34.7%) were transfused to patients with normal pretransfusion coagulation tests. This implies that the acceptance of the CTDSS and an understanding of a physician's ordering behavior are important issues to improve the medical management quality in FFP transfusion. We suggest that an indication must be chosen before completing the transfusion order in the CTDSS and that pretransfusion coagulation results should be shown on the requisition form when ordering, except for patients requiring plasma exchange or who have some other life-threatening conditions. If even one of the aforementioned criteria remains unsatisfied, the transfusion requisition could be rejected by the CTDSS. If the ordering physician chooses the indication as other conditions approved by a physician in the blood bank, the blood bank should contact the ordering physician to evaluate the appropriateness of transfusion. This might make the CTDSS more flexible and practical. Some studies have shown that inappropriate FFP use is more common in university hospitals than in smaller, peripheral hospitals, 32, 33 which is because of the greater complexity of cases and the greater use of blood components in the university hospitals. Both factors could limit the possibility of adherence to guidelines.
Previous studies have found widespread deficiencies in physicians' knowledge regarding transfusion indications and risks. 31 Interventions such as educational conferences or multifaceted interventions are considered most effective in promoting changes in physician behavior. 34, 35 Education about transfusion medicine should be arranged for all medical staff, and the CTDSS should be designed to be more powerful and effective enough to intervene in the appropriateness of transfusion practice. Appropriate transfusion practice may reduce the overuse of blood components, avoid transfusion risks, and decrease unnecessary health care costs, as we reported previously. 12 Further studies are warranted to investigate the significance and efficacy of the CTDSS application for making decisions regarding clinical FFP transfusion.
